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I. Introduction
In 1998, the American Heart Association convened Preven-
tion Conference V to examine strategies for the identification
of high-risk patients who need primary prevention. Among
the strategies discussed was the measurement of markers of
inflammation.1 The Conference concluded that “many of
these markers (including inflammatory markers) are not yet
considered applicable for routine risk assessment because of:
(1) lack of measurement standardization, (2) lack of consis-
tency in epidemiological findings from prospective studies
with endpoints, and (3) lack of evidence that the novel marker
adds to risk prediction over and above that already achievable
through the use of established risk factors.” The National
Cholesterol Education Program Adult Treatment Panel III
Guidelines identified these markers as emerging risk
factors,1a which could be used as an optional risk factor
measurement to adjust estimates of absolute risk obtained
using standard risk factors. Since these publications, a large
number of peer-reviewed scientific reports have been pub-
lished relating inflammatory markers to cardiovascular dis-
ease (CVD). Several commercial assays for inflammatory
markers have become available. As a consequence of the
expanding research base and availability of assays, the
number of inflammatory marker tests ordered by clinicians
for CVD risk prediction has grown rapidly. Despite this, there
has been no consensus from professional societies or govern-
mental agencies as to how these assays of markers of
inflammation should be used in clinical practice.
On March 14 and 15, 2002, a workshop titled “CDC/AHA
Workshop on Inflammatory Markers and Cardiovascular
Disease: Applications to Clinical and Public Health Practice”
was convened in Atlanta, Ga, to address these issues. The
goals of this workshop were to determine which of the
currently available tests should be used; what results should
be used to define high risk; which patients should be tested;
and the indications for which the tests would be most useful.
These determinations should assist the clinician in selecting
tests judiciously and appropriately and should assist health-
care payers in making decisions about the support of such
tests in clinical practice.
To achieve this goal, the workshop set down five
objectives:
(1) To review the scientific evidence from diverse sources
to examine the association between several inflammatory
markers (high-sensitivity C-reactive protein [hs-CRP], serum
amyloid A [SAA], white blood cell [WBC] count, fibrinogen,
etc) and CVDs, including the strength, consistency, indepen-
dence, and generalizability of the data.
(2) To consider the clinical chemistry and various assays of
inflammatory markers, to identify which may be the best
assays to use in identifying persons at risk.
(3) To identify areas in which questions persist in order to
foster additional research on inflammatory markers and CVD.
(4) To recommend which tests should be performed for
which patients and in which clinical settings, for the purpose
of risk stratification, therapeutic monitoring, and other clini-
cal applications, on the basis of the scientific evidence.
(5) To explore the public health implications of an associ-
ation between inflammatory markers and CVD.
This conference was jointly sponsored by the Centers for
Disease Control and Prevention and the American Heart
Association. Specifically, the National Center for Chronic
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Disease Prevention and Health Promotion and the National
Center for Environmental Health provided financial and
organizational support. The American Heart Association, its
Expert Panel on Population and Prevention Science, and its
Councils on Atherosclerosis, Thrombosis, and Vascular Bi-
ology; Clinical Cardiology; and Epidemiology and Preven-
tion coordinated the workshop, with support from unre-
stricted educational grants from industry sponsors (see
Acknowledgments). The writing group, endorsed by the
Science Advisory and Coordinating Committee of the Amer-
ican Heart Association, included representation from the
above-mentioned agencies and organizations, as well as the
American Association for Clinical Chemistry and the Amer-
ican College of Cardiology.
The workshop consisted of 11⁄2 days of presentations and
discussions of topics relevant to inflammatory markers and
CVD. The first half of the workshop consisted of state-of-
the-art lectures by recognized authorities in the field. The
second half consisted of three concurrent discussion groups
on the issues related to laboratory science, clinical science,
and population science. The recommendations of this work-
shop are derived from these discussion groups. The invited
lectures and discussion group findings will be published in a
separate document. A complete list of participants, organized
by discussion group, is listed at the end of this publication
(Appendix 1).
This document uses the major findings and conclusions of
the Workshop to develop a statement that has been fully
reviewed and approved by The Science Advisory and Coor-
dinating Committee of AHA and the CDC. It crafts a
statement that considers the best available evidence for an
association between inflammatory markers and CVD. In this
consideration, the US Surgeon General’s criteria for inference
of causality were used in examination of the evidence—
namely, the strength, temporality, dose-response relationship,
biological plausibility, and consistency of the evidence were
reviewed.1b The quality of scientific evidence for an associ-
ation was assessed,2 and the American College of Cardiolo-
gy/American Heart Association classification of recommen-
dations and levels of evidence were used (see Appendix 2).
Moreover, consideration of recommendations for the use of
inflammatory markers as screening tools also employed an
evidence-based approach.3 This included evidence from prop-
erly designed, randomized trials that intervention in
screening-positive persons benefited the patients, and it
included consideration of the potential benefits, harm, differ-
ences in performance between different groups of people, use
in various screening strategies, and cost-effectiveness.
II. Evidence for Inflammation as a Key
Pathogenetic Mechanism in Atherosclerosis
A role for inflammation has become well established over the
past decade or more in theories describing the atherosclerotic
disease process.4,5 From a pathological viewpoint, all stages,
ie, initiation, growth, and complication of the atherosclerotic
plaque,6,7 might be considered to be an inflammatory re-
sponse to injury. The major injurious factors that promote
atherogenesis—cigarette smoking, hypertension, atherogenic
lipoproteins, and hyperglycemia—are well established. These
risk factors give rise to a variety of noxious stimuli that elicit
secretion of both leukocyte soluble adhesion molecules,
which facilitate the attachment of monocytes to endothelial
cells, and chemotactic factors, which encourage the mono-
cytes’ migration into the subintimal space. The transforma-
tion of monocytes into macrophages and the uptake of
cholesterol lipoproteins are thought to initiate the fatty streak.
Further injurious stimuli may continue the attraction and
accumulation of macrophages, mast cells, and activated T
cells within the growing atherosclerotic lesion. Oxidized
low-density lipoproteins may be one of several factors that
contribute to loss of smooth muscle cells through apoptosis in
the atherosclerotic plaque cap, and secretion of metallopro-
teinases and other connective tissue enzymes by activated
macrophages may break down collagen, weakening the cap
and making it prone to rupture. This disruption of the
atherosclerotic plaque then exposes the atheronecrotic core to
arterial blood, which induces thrombosis. Thus, virtually
every step in atherogenesis is believed to involve cytokines,
other bioactive molecules, and cells that are characteristic of
inflammation.
These pathophysiological insights provide potential targets
for measurement as a means to identify and monitor the
ongoing inflammatory process (Figure 1). Potential targets
for measurement include proinflammatory risk factors such
as oxidized low-density lipoproteins, proinflammatory cyto-
kines (eg, interleukin-1, tumor necrosis factor-), adhesion
molecules (eg, intercellular adhesion molecule-1, selectins),
inflammatory stimuli with hepatic effects (eg, interleukin-6)
or the products of the hepatic stimulation, such as SAA,
C-reactive protein (CRP), and a host of other acute-phase
reactants. Finally, other indicators of cellular responses to
inflammation, such as elevated leukocyte count, might be
evaluated. It should be pointed out that this inflammatory
cascade may have sources other than an atherosclerotic
coronary artery, including atherosclerosis in other arteries, as
well as systemic inflammation (eg, connective tissue dis-
eases) and local infections (eg, gingivitis, prostatitis, bronchi-
tis, urinary tract infections, gastric inflammation). These
systemic inflammations may result in elevated levels of
inflammatory markers that may be incorrectly attributed to
Figure 1. The inflammatory cascade. IL indicates interleukin;
ICAM, intercellular adhesion molecule; and HSP, heat shock
protein.
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atherosclerotic CVD. Nonetheless, increasing recognition of
the inflammatory component of atherogenesis provides the
biological plausibility for the potential use of inflammatory
markers as indicators of atherogenesis or as predictors of
atherosclerotic complications.
III. Characteristics Desirable in a CVD
Risk Predictor
Understanding of the inflammatory cascade in Figure 1
allows the consideration of a number of inflammatory mark-
ers as potentially useful predictors of prevalent or incident
CVD (Table 1). Such markers, however, may not be useful in
the clinical arena unless they possess additional characteris-
tics.8 These include: (1) the ability to standardize the assay
and to control the variability of the measurement; (2) inde-
pendence from established risk factors; (3) association with
CVD clinical end points in observational studies and clinical
trials; (4) the presence of population norms to guide interpre-
tation of results; (5) ability to improve the overall prediction
beyond that of traditional risk factors; (6) generalization of
results to various population groups; and (7) acceptable cost
of the assays. The use of the marker is also affected by the
type of relationship with CVD (eg, linear, nonlinear, dichot-
omous). These characteristics then can be examined in the
inflammatory markers currently under consideration.
Several features of the relationship between inflammatory
markers and CVD end points should be taken into account.
First, is the assayed substance a risk factor or a risk marker
(Figure 2)? In other words, does the analyte measure a step in
the causal pathway leading to atherosclerosis or the disease
process itself? Next, which CVD end points are being
considered? Inflammatory markers may relate differently to
prevalent atherosclerotic disease than to acute or chronic
syndromes in the coronary, cerebral, or peripheral arterial
beds. Third, does the ability of the marker to predict CVD end
points differ over the timeframe of the events, ie, short term
versus long term? Fourth, does measurement of the marker
indicate efficacy of therapy or changing prognosis? Finally, is
the use of the test cost-effective? Namely, can the incremental
cost of the test be justified by reductions in other costs or
improvements in outcomes? Conversely, are there indirect
costs of a positive test that are prohibitive?
IV. Laboratory Tests Available to
Assess Inflammation
A sizable number of studies have examined the inflamma-
tion–CVD association through measurement of a variety of
analytes. Only some of these assays, however, are currently
employable in clinical settings, after consideration of the
stability of the analyte, the commercial availability of assays,
the standardization of those assays to allow comparison of
results, and the precision of the assays as measured by the
coefficient of variation. Table 2 summarizes the currently
available assays for inflammatory markers. Several markers
are only stable when frozen, which limits their use to research
settings. Likewise, only the acute-phase reactants (fibrinogen
and CRP) and WBC count have widely available assays. CRP
has a proficiency-testing program from the College of Amer-
ican Pathologists. A program to standardize CRP testing is
underway at the Centers for Disease Control and Prevention.
Most of the acute-phase reactant assays have acceptable
coefficients of variation.
These comparisons of the various inflammatory markers
favor CRP from the clinical chemistry perspective. It needs to
be emphasized that the assays considered in Table 2 were for
hs-CRP with acceptable precisions down to or below 0.3
mg/L. It is within these lower, previously “normal” ranges
that the hs-CRP levels seem to have predictive abilities for
CVD events. Although new assays of other inflammatory
markers, with precision, standardization, and other character-
istics that are superior to those of the current assays, may
become available, the hs-CRP assay represents the best
candidate at this time.
V. Evidence for Association of Inflammatory
Markers With CVD: Clinical and
Epidemiological Studies
A. Prediction of Incident CVD Events:
Primary Prevention
Several older prospective epidemiological studies have doc-
umented an association between inflammatory markers such
as WBC count and fibrinogen9–11 and CVD. In general, these
analyses have shown gradation of risk across the measured
ranges. Multivariate adjustment for other risk factors did not
remove the association between CVD incidence and WBC
count or fibrinogen. These data, along with newer studies of
hs-CRP and SAA, regardless of their utility in current clinical
Figure 2. Alternative models for the role of inflammatory mark-
ers in CVD: risk factor or risk marker?
TABLE 1. Inflammatory Markers for Consideration as
Predictors of Cardiovascular Risk
Adhesion molecules
Cytokines
Acute-phase reactants
Fibrinogen
SAA
CRP
WBC count
Other (eg, erythrocyte sedimentation rate)
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practice, add consistency to the inflammatory marker–CVD
association.
Newer analyses have examined analytes such as hs-CRP,
SAA, and other acute-phase reactants or cytokines. Many of
the newer studies did not measure these factors in all patients
but rather performed nested case-control studies. This study
design is valid in terms of estimation of relative risk and
temporality of the level of marker predating the CVD events,
and often uses strict matching criteria to limit confounding.
However, it does not allow incidence of clinical CVD events
to be measured in various strata. Rather, relative odds
estimate relative risks across various strata of inflammatory
markers. A similar number of large prospective studies
corroborate the findings of the nested case-control studies,
however.12–23
A meta-analysis of prospective population-based studies
has compared persons in the lower tertile of hs-CRP with
those in the upper tertile.15,16 With a good consistency
between studies, a relative odds of 2.0 (95% CI 1.6–2.5) for
major coronary events was observed for the upper tertile with
the lowest tertile used as a reference. These prospective
studies include men,17,18 women,19,20 and the elderly.21–23
Large population-based studies such as the study from the
MONICA (MONItoring trends and determinants in CArdio-
vascular disease) Augsberg Center in Germany,12 the Athero-
sclerosis Risk in Communities Study,24 the Women’s Health
Study,13 the Honolulu Heart Study,14 and the NHANES
(National Health And Nutrition Examination Survey) studies
(cross-sectional25,26) are also represented. In general, most
studies show a dose-response relationship between the level
of hs-CRP and risk of incident coronary disease. Recent
studies also suggest association with incidence of sudden
death27,28 and peripheral arterial disease.29 The strength of the
association, however, has been modest in some studies.24–26 It
should be noted that studies of other, newer inflammatory
markers such as interleukin-6 and SAA show similar re-
sults.20,30 A notable characteristic of all these studies is their
limitation to white North American or European populations,
with the exception of Japanese-American men in the Hono-
lulu Heart Study.14,31 Data are limited for persons of African,
South Asian, or Native American descent, who may be at
particularly high risk for CVD, and for other racial/ethnic
groups. Race and ethnicity did not appear to be an effect
modifier of the hs-CRP–stroke association in one study.25
The ability of hs-CRP to add to the predictive capacity of
other, established risk factors has been examined in several
studies. Through stratification or multivariable statistical
adjustment, hs-CRP retains an independent association with
incident coronary events after adjusting for age, total choles-
terol, HDL cholesterol, smoking, body mass index, diabetes,
history of hypertension, exercise level, and family history of
coronary disease.13,32,33 In some studies, the magnitude of the
relative risk in the upper percentiles of hs-CRP is attenuated
after this adjustment, including loss of statistical signifi-
cance.34 Recent studies demonstrate the capability of elevated
hs-CRP to predict coronary events in women after adjusting
for risk factors used in the Framingham risk score,13 and in
the elderly with extensive adjustment for CVD risk factors
and measures of subclinical atherosclerosis.21 Relatively few
studies have adjusted for body mass index or for measures of
diabetes or glucose metabolism.
Inflammatory markers such as hs-CRP have not been good
predictors of the extent of atherosclerotic disease, showing
poor correlations with results of tests that quantify the extent
TABLE 2. Assays of Inflammatory Markers for Potential Clinical Use*
Analyte Stability
Assay
Availability
World Health Organization
Standards Available?†
Interassay
Precision
Soluble adhesion molecules (eg,
E-selectin, P-selectin, intracellular
adhesion molecule-1, vascular cell
adhesion molecule-1)
Unstable (unless frozen) Limited No CV15%
Cytokines (eg, interleukin-1, -6, -8,
and -10 and tumor necrosis factor-)
Unstable (unless frozen) Few Yes (Reference 1) CV15%
Acute-phase reactants
Fibrinogen Unstable‡ (unless frozen) Many Yes§ (Reference 2) CV8%
SAA Stable One Yes (Reference 3) CV9%
hs-CRP Stable Many Yes (Reference 4) CV10%
WBC count Stable Many Yes CV3%
*Courtesy of William Roberts, MD, PhD. CV indicates coefficient of variation.
†Information on specific standards is available at the following World Health Organization web site: http://www.who.int.biologicals.
‡In correctly anticoagulated blood, stable for at least 12 hours on ice or several hours at room temperature.
§World Health Organization standard available only for mass assay, not for functional assays most commonly in use.
References
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of atherosclerosis, such as Doppler ultrasound scans of
carotid arteries35 and electron beam computerized tomogra-
phy for coronary calcium.36,37 Nonetheless, some studies
suggest a positive correlation,38–41 and more research is
required to fully define the relationship between inflamma-
tory markers and atherosclerotic mass. Inflammatory markers
may measure other characteristics than atherosclerotic mass.
These characteristics may include the activity of lymphocyte
and macrophage populations within plaque or the degree of
plaque destabilization and ongoing ulceration or thrombosis.
B. Prediction of Recurrent CVD Events and
Death: Secondary Prevention
A growing number of studies have examined inflammatory
markers as predictors of recurrent CVD and death in different
settings, including the short-term risk, long-term risk, and risk
after revascularization procedures such as percutaneous cor-
onary intervention (PCI), including the risk of restenosis.
Although several markers have been studied, the strongest
association with prognosis has been with fibrinogen and
hs-CRP. hs-CRP consistently predicts new coronary events in
patients with unstable angina and acute myocardial infarc-
tion.42–51 Most of these studies have been long term, but some
in-hospital survivorship studies52–54 have also shown an
association.
For patients with acute coronary syndromes, cutpoints for
elevated hs-CRP different than those for prediction in asymp-
tomatic patients may be useful. For example, a level of 10
mg/L in acute coronary syndromes may have better predictive
qualities, whereas a level of 3 mg/L may be more useful in
patients with stable coronary disease.
Many analyses have adjusted for other prognostic factors,
demonstrating continued predictive capacity with hs-CRP. In
acute coronary syndromes, hs-CRP predicts recurrent myo-
cardial infarction independent of troponins, which suggests it
is not merely a marker for the extent of myocardial dam-
age.52–54 Recent data also suggest that hs-CRP may be a
marker for risk of restenosis after PCIs,55,56 but all studies are
not in agreement with these results.57 Elevated hs-CRP levels
also seem to predict prognosis and recurrent events in patients
with stroke58,59 and peripheral arterial disease.60 These data
suggest that hs-CRP may have a role in risk stratification of
patients with established CVD, although more data are
needed that compare the prognostic value of elevated levels
of hs-CRP with other prognostic measures currently in use.
C. Sources of Variability of Inflammatory Markers
Generally, the precision and reproducibility of inflammatory
marker assays such as the acute-phase reactants have been
acceptable (Table 2). For example, the coefficient of variation
of hs-CRP assays is generally 10% from the 0.3- to
10-mg/L range.61 Considerable within-individual variability
exists, however, for both hs-CRP and fibrinogen.62,63 In
general, although CRP is an acute-phase reactant and as such
has higher within-subject variability than an established risk
factor such as serum cholesterol, it also has a broader
distribution in the population. The final result is that, in a
manner similar to cholesterol, two separate measurements of
hs-CRP are adequate to classify a person’s risk level and to
account for the increased within-individual variablility.63,64
The distribution of the logarithm of hs-CRP level is a normal
distribution, and the nontransformed values are skewed to-
ward the higher values, with most populations showing
95% of subjects with hs-CRP values of 10 mg/L. There
seems to be population-to-population consistency in this,
though as previously stated, data for racial and ethnic popu-
lations are limited (eg, NHANES III).
Sources of variation of inflammatory markers have been
studied to varying degrees.62–64 There seems to be little
seasonal or diurnal variation with hs-CRP.65 Several factors
have been identified as being associated with increased or
decreased levels of hs-CRP (Table 3); this list is likely
incomplete. For example, body weight and the metabolic
syndrome are consistently associated with elevated hs-CRP,
and weight loss is associated with reduction in hs-CRP levels,
with some authors suggesting that hs-CRP is merely a marker
for obesity and insulin resistance.66–74 This association of
hs-CRP with these conditions is poorly defined from a
mechanism standpoint, and is possibly due to coassociation
with prevalent vascular disease. Individuals with evidence of
active infection, systemic inflammatory processes, or trauma
should not be tested until these conditions have abated. An
hs-CRP level of10 mg/L, for example, should be discarded
and repeated in 2 weeks to allow acute inflammations to
subside before retesting.
D. Studies of Use of Inflammatory Markers in
Clinical Practice
Despite the ability of some inflammatory markers to predict
incident or recurring events, various analyte characteristics
and within-individual variation seem to limit the analytes to
hs-CRP and possibly fibrinogen. The specific clinical settings
in which hs-CRP or other factors would be most useful,
however, need to be defined by careful clinical investigations,
including clinical trials. As noted, the levels of inflammatory
markers do not seem to correlate well with extent of angio-
graphically defined atherosclerosis,51 and therefore seem to
be of little value in selection of patients for coronary artery
procedures. Inflammatory markers may have greater potential
as a means to augment risk assessment in the identification of
persons who should be considered for lipid-lowering, anti-
platelet, or other cardioprotective drug therapies, as well as
TABLE 3. Patient Characteristics and Conditions Associated
With Increased or Decreased Levels of hs-CRP
Increased Levels Decreased Levels
Elevated blood pressure
Elevated body mass index Moderate alcohol
consumption
Cigarette smoking Increased activity/endurance
exercise
Metabolic syndrome/diabetes mellitus Weight loss
Low HDL/high triglycerides Medications
Estrogen/progestogen hormone use Statins
Chronic infections (gingivitis, bronchitis) Fibrates
Chronic inflammation (rheumatoid arthritis) Niacin
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TABLE 4. Recommendations for Clinical and Public Health Practice
Procedure Should
Be Performed
(Class I)
Conflicting Evidence/Opinion:
Weight in Favor of
Usefulness/Efficacy
(Class IIa)
Conflicting Evidence/Opinion:
Usefulness/Efficacy Less Well
Established
(Class IIb)
Procedure Should Not Be
Performed
(Class III)
Population Science 1. The entire adult population
should not be screened for hs-CRP
for purposes of cardiovascular risk
assessment.
(Class III, Level of Evidence C)
Clinical Practice
1. Measurement of hs-CRP is an
independent marker of risk and, in
those judged at intermediate risk
by global risk assessment (10 to
20% risk of CHD per 10 years), at
the discretion of the physician, may
help direct further evaluation and
therapy in the primary prevention
of CVD. The benefits of such
therapy based on this strategy
remain uncertain.
(Class IIa, Level of Evidence B)
2. Measurement of hs-CRP is an
independent marker of risk and
may be used at the discretion of
the physician as part of a global
coronary risk assessment in adults
without known CVD. The benefits
of this strategy remain uncertain.
(Class IIb, Level of Evidence C)
3. hs-CRP levels may be useful in
motivating patients to improve
lifestyle behaviors. The benefits of
this strategy remain uncertain.
(Class IIb, Level of Evidence C)
4. Patients with persistently
unexplained, marked elevation of
hs-CRP (10mg/L) after repeated
testing should be evaluated for
noncardiovascular etiologies.
(Class IIa, Level of Evidence B)
5. Other inflammatory markers
(cytokines, other acute-phase
reactants) should not be measured
for the determination of coronary
risk in addition to hs-CRP.
(Class III, Level of Evidence C)
6. In patients with stable coronary
disease or acute coronary
syndromes, hs-CRP measurement
may be useful as an independent
marker of prognosis for recurrent
events, including death, MI, and
restenosis after PCI. The benefits of
therapy based on this strategy
remain uncertain.
(Class IIa, Level of Evidence B)
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for increased emphasis on therapeutic lifestyle changes. If the
patient is already targeted for these treatments according to
current guidelines (eg, secondary prevention), then a level of
inflammatory marker is less useful. A better potential use
may be in those patients at baseline risk for whom an
additional risk predictor may provide support for or against
additional lifestyle or drug therapies.75–77 Post hoc analyses
from two randomized controlled trials (AFCAPS/TexCAPS
[Air Force/Texas Coronary Atherosclerosis Prevention
Study] trial of lovastatin versus placebo77 and the Physicians’
Health Study of aspirin versus placebo76) both suggest that
persons with elevated hs-CRP levels have a larger absolute
risk reduction in the intervention groups, which supports the
potential utility of hs-CRP to target patients for primary
preventive interventions.
One potential use for markers that might be considered is
that of monitoring of the effects of therapy, such as an
HMG-CoA reductase inhibitor. For example, if the marker
does not fall, treatment might be intensified. HMG-CoA
reductase inhibitors do seem to reduce hs-CRP levels,78 but
the response is very heterogeneous, with many nonresponders
and a few hyper-responders contributing to the reduction in
mean hs-CRP level. Unfortunately, it is not known if the
responders with lowered hs-CRP levels have a greater reduc-
tion in risk than the nonresponders. Conversely, despite
recent indications of possible increased risk with the use of
estrogen in hormone replacement therapy (HRT)79 and the
finding that hs-CRP is increased with estrogen use,80 it is not
yet possible to conclude that an increased hs-CRP brought
about by estrogen use is an indicator of increased CVD risk.
TABLE 4. Continued
Procedure Should
Be Performed
(Class I)
Conflicting Evidence/Opinion:
Weight in Favor of
Usefulness/Efficacy
(Class IIa)
Conflicting Evidence/Opinion:
Usefulness/Efficacy Less Well
Established
(Class IIb)
Procedure Should Not Be
Performed
(Class III)
7. Application of secondary
prevention measures should not
depend on hs-CRP determination.
(Class III, Level of Evidence A)
8. Application of management
guidelines for acute coronary
syndromes should not be
dependent on hs-CRP levels.
(Class III, Level of Evidence A)
9. Serial testing of hs-CRP should
not be used to monitor effects of
treatment.
(Class III, Level of Evidence C)
Laboratory Testing
1. Of current inflammatory markers
identified, hs-CRP has the analyte
and assay characteristics most
conducive to use in practice.
(Class IIa, Level of Evidence B)
2. Measurement of markers should
be done twice (averaging results),
optimally two weeks apart, fasting
or nonfasting in metabolically
stable patients. If hs-CRP level is
10 mg/L, test should be repeated
and patient examined for sources
of infection or inflammation.
(Class IIa, Level of Evidence B)
3. hs-CRP levels, using
standardized assays, categorize
patients as follows:
Relative Risk Category and
Average hs-CRP Level
Low 1 mg/L
Average 1.0 to 3.0 mg/L
High 3.0 mg/ L
(Class IIa, Level of Evidence B)
4. hs-CRP results should be
expressed as mg/L only.
(Class I, Level of Evidence C)
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Thus, a role of these markers in the monitoring of therapy has
not been established.
VI. Recommendations for Use of
Inflammatory Markers in Clinical and Public
Health Practice
The writing group examined the currently available evidence
in the topic areas of laboratory, clinical, and population
sciences in order to derive recommendations for use of
inflammatory markers in clinical practice. The recommenda-
tions were classified, and the evidence for each recommen-
dation was then rated according to the system used by the
American College of Cardiology/American Heart Associa-
tion (Appendix 2, Table 5). Table 4 summarizes the recom-
mendations, with Quality of Evidence of Class I constituting
enough evidence that clinicians and practitioners should use
inflammatory markers in laboratory, clinical, and public
health practices. Quality of Evidence of Class IIa and Evi-
dence Level of A or B constitutes enough evidence that
clinicians and practitioners might reasonably use inflamma-
tory markers. Conversely, Quality of Evidence Class III
supports a recommendation against the use for that specific
purpose.
From the laboratory medicine/clinical chemistry perspec-
tive, the first question is: “If inflammatory markers are to be
used, which test should be recommended?” Current evidence
supports the use of hs-CRP as the analyte of choice, after
consideration of the various analytes’ stabilities; the analytes’
assay precision, accuracy, and availability; and the availabil-
ity of standards for proper assay calibration (Table 2).
Additional analytes, improved assays, or evidence for bene-
fits of combinations of assays may in the future be found to
have advantages, but further research is needed (see Research
Recommendations). Therefore, the measurement of alterna-
tive or additional analytes is not recommended at this time
(Clinical Practice Recommendation No. 5 in Table 4).
The next question is: “How should hs-CRP be measured?”
The hs-CRP assay, to reduce within-individual variability,
should be performed in a metabolically stable person without
obvious inflammatory or infectious conditions. Results for
hs-CRP should be expressed as mg/L only. Two assays,
averaged, fasting or nonfasting, and optimally 2 weeks apart,
provide a more stable estimate of level of this marker. If a
level of 10 mg/L is identified, there should be a search
initiated for an obvious source of infection or inflammation,
which could obscure any prediction of coronary risk that
might be attributed to the elevated level. That result of 10
mg/L should then be discarded and the hs-CRP measured
again in 2 weeks.
The cutpoints of low risk (1.0 mg/L), average risk (1.0 to
3.0 mg/L), and high risk (3.0 mg/L) correspond to approx-
imate tertiles of hs-CRP in the adult population. The high-risk
tertile has an 2-fold increase in relative risk compared with
the low-risk tertile. These tertiles are based on distributions of
hs-CRP samples from 15 populations involving 40 000
persons gathered for the purpose of this workshop, allowing
adequate definition of the population distribution. In general,
the high-risk category includes the skewed tail of the
distribution.
After the identification of hs-CRP as the current analyte of
choice, the next question is: “When and in whom should this
inflammatory marker be measured?” Key to this discussion
are the purpose for its measurement and the likelihood that
further diagnostic and therapeutic plans might change on the
basis of the test results. No clinical trials have been completed
in which a population has been randomly allocated to
screening for hs-CRP and compared with a control population
not allocated to hs-CRP screening and both groups followed
up prospectively to determine the benefits and harms of the
screening. In particular, there continue to be few data on the
cost-effectiveness of screening with inflammatory markers,
taking into account further testing and treatment of persons
classified as having high risk for CVD or the possibility of
reduced testing and treatment of persons classified as being at
low risk. Evidence-based practice does not require clinical
trial evidence but rather requests that evidence currently
available be taken into account in the formulation of recom-
mendations. Such trials, however, are a recognized area for
needed research (see Research Recommendations).
The best evidence to date supports the use of hs-CRP as an
independent predictor of increased coronary risk. Although
evidence for benefit or harm is not conclusive (Quality of
Evidence IIb, Level C) for using this marker in all patients
and in typical practice settings as part of a global risk
assessment, the Writing Group endorses (at Evidence Level
B) the optional use of hs-CRP to identify patients without
known CVD who may be at higher absolute risk than
estimated by major risk factors. Specifically, those patients at
intermediate risk (eg, 10% to 20% risk of coronary heart
disease (CHD) over 10 years), in whom the physician may
need additional information to guide considerations of further
evaluation (eg, imaging, exercise testing) or therapy (eg, drug
therapies with lipid-lowering, antiplatelet, or cardioprotective
agents), may benefit from measurement of hs-CRP. Those
who have a 10-year risk of20% are designated as CHD risk
equivalents and already qualify for intensive medical inter-
ventions. This recommendation assumes the assessment of
traditional cardiovascular risk factors and the calculation of
an absolute risk score before measurement of hs-CRP.75 The
Writing Group discourages use of hs-CRP as an alternative to
major risk factors for risk assessment. Treatment of patients
with elevated hs-CRP on the basis of the hs-CRP alone has
limited data to support it at the present time, and would require
a prospective clinical trial to prove efficacy. The further assess-
ment of patients with highly elevated hs-CRP (10 mg/L) for
noncardiovascular causes of inflammation was also endorsed.
Thus, clinical judgment is required whether to adjust risk within
this risk category by measurement of hs-CRP.
An interesting but untested use for hs-CRP is to motivate
persons with moderate to high risk levels to improve their
lifestyles (eg, smoking cessation, dietary modification, exer-
cise, weight loss) or to comply with drug therapies. Limited
data support the effectiveness of this particular application at
the present time, and it would require a randomized, con-
trolled trial to prove efficacy.
Measurement of hs-CRP also may be useful in the estima-
tion of prognosis in patients who need secondary preventive
care, such as those with stable coronary disease or acute
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coronary syndromes and those who have undergone PCI. This
information may be useful in patient counseling because it
offers motivation to comply with proven secondary preven-
tive interventions. Such prognostication may lead to more
aggressive diagnostic testing or treatment options. However,
current guidelines for secondary prevention generally recom-
mend, without measuring hs-CRP, the aggressive application
of secondary preventive interventions. Thus, secondary pre-
ventive care and acute coronary syndrome interventions
should not depend on hs-CRP levels because the evidence for
their effectiveness is already strong (Recommendations 7 and
8), so the utility of hs-CRP in secondary prevention seems to
be more limited. Moreover, little evidence supports the use of
serial testing for hs-CRP as a means to measure disease
activity or to monitor therapy (Recommendation 9). Thus, the
role of hs-CRP in secondary prevention likely is limited
because of the reduced likelihood that it will alter
management.
Finally, the entire adult population should not be screened
for hs-CRP for purposes of cardiovascular risk assessment.
Little evidence supports a recommendation for widespread
screening for hs-CRP as a public health measure (Class III,
Level of Evidence C). Such a recommendation would have to
be based on additional evidence from studies of potential
benefits and harm for such a screening initiative.81
VII. Recommendations for Research
A. Basic/Laboratory Sciences
The recognition that the inflammatory response is a key
mechanism in the pathogenesis of atherosclerosis and its
related clinical syndromes has provided a new paradigm with
important implications for CVD research at the basic, clini-
cal, and population levels. A discussion of the needs for
further elucidation of basic mechanisms by which inflamma-
tion leads to clinical disease is beyond the scope of this
report. One issue of relevance, however, is the current
designation of inflammatory markers as risk markers in
distinction to risk factors. A risk factor is associated with a
disease by virtue of its participation in the causal pathway
leading to the disease. A risk marker is statistically associated
with the disease but need not be causally linked; in fact, it
may be a measure of the disease process itself (Figure 2). In
the case of inflammatory markers, the association might
reflect a response to other, established risk factors (eg,
obesity, diabetes, hyperlipidemia, cigarette smoking) or due
to inflammatory processes as part of atherosclerotic disease.
Given the lack of association between hs-CRP levels and the
extent of atherosclerosis quantified by imaging technologies,
the risk marker model seems to concur best with current
evidence. Some evidence, however, also implicates a possible
role for hs-CRP in the causation of atherosclerosis.82–85
Furthermore, it is biologically plausible that CRP has a role in
plaque instability as an explanation for the close relationship
between hs-CRP and clinical syndromes as compared to its
relationship to the extent of atherosclerosis.5–7 Additional
investigation of the role of hs-CRP and other inflammatory
markers in atherogenesis is needed to fully understand this
issue.
Further clinical chemistry and laboratory medicine re-
search is needed to assure optimal measurement of the
presence, level, and perhaps type of inflammation in an
individual patient. As identified in Table 2, additional ana-
lytes hold promise as inflammatory markers but are currently
limited by their instability, lack of available assays applicable
to clinical rather than research settings, lack of precision, and
lack of available standards. Fibrinogen levels, for example,
have long been independently associated with incident coro-
nary disease in numerous studies. Newer assays of fibrinogen
that use immunologic methods need to be investigated to
determine if they predict CVD as effectively as the previous
functional assays and if they offer potential benefits from
standardization and improved precision.
Another area in need of investigation is the use of combi-
nations of inflammatory markers in the classification of CVD
risk. Different analytes might be measured concurrently or
sequentially to improve the sensitivity or specificity of the
screening process. Another need is to identify markers or
combinations of markers with greater specificity for athero-
sclerotic risk. Current assays are not specific for atheroscle-
rosis and thus are not useful in the setting of other systemic
inflammatory or infectious processes.
Despite the endorsement of hs-CRP as the current analyte
of choice, there remains much to learn about optimizing its
application to risk assessment. There needs to be continued
standardization and performance testing for hs-CRP assays
that are available to the clinical practice of medicine, includ-
ing performance criteria for these assays, so that only assays
with adequate precision and accuracy are recommended.
There need to be additional comparisons of hs-CRP assays
between serum samples and those plasma samples collected
in heparin or in EDTA. Finally, additional work needs to be
invested in the examination of CVD risk at various hs-CRP
levels to better refine the cutpoints used for cardiovascular
risk prediction and to assign levels of absolute risk to each
stratum.
B. Clinical Sciences
An important conclusion from Table 4 is the striking lack of
Level A evidence (derived from multiple randomized clinical
trials). This endorses the need for not only additional inves-
tigation of the hs-CRP–CVD association but also the study of
the application of these markers to cost-effective medical
care. Thus, most current evidence has been derived from
observational studies or post hoc analyses of randomized
trials in which the intervention was not hs-CRP screening and
the interventions were not intended to alter inflammation.
Therefore, randomized clinical trials need to be performed
to test whether risk categorization by hs-CRP leads to (1)
therapeutic risk reductions in additional patients who are not
currently identified or (2) a reduction in the number of
patients in need of treatment by identifying low-risk groups
that heretofore had been recommended for further diagnostic
testing or aggressive interventions. Furthermore, experimen-
tal studies need to be carried out to determine whether
reductions in hs-CRP levels from nonpharmacological and
pharmacological interventions are associated with reductions
in CVD risk. These studies should then clarify strategies,
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based on hs-CRP levels, for additional treatment planning,
further diagnostic testing, and change in recommended tar-
gets for treatments (such as LDL cholesterol or blood
pressure levels). The importance of hs-CRP reductions that
have been observed with lipid-lowering drugs and other
cardioprotective agents needs to be much better understood.
Similarly, the meaning of a continued elevation of hs-CRP
levels after acute or chronic management of acute coronary
syndromes needs to be elucidated. Should such patients
undergo further imaging or more aggressive therapy? Exper-
imental rather than exclusively observational study designs
likely are essential to sort out many of these issues.
Several specific issues need resolution over the short term
to assure optimal benefits from current recommendations.
First, can hs-CRP be used quantitatively as part of estimation
of absolute risk for coronary disease? Recent data suggest
that an hs-CRP level, with the prior probability from a
Framingham risk score, be used to increase or reduce the risk
estimated for women.13 Additional studies are needed to
improve the precision of the absolute risk estimates. Multi-
pliers were developed by the Framingham Heart Study for
fibrinogen, for example.10 Second, postmenopausal HRT
increases hs-CRP.80,86,87 Recent evidence suggests that an
elevated hs-CRP identifies an increased coronary risk in
women on HRT, although it is not yet known whether
elevations in hs-CRP due to HRT are important predictors of
risk.15,80 Finally, does drug therapy with antiinflammatory
drugs such as aspirin, COX-II inhibitors, or other therapies
administered at the time of hs-CRP measurement alter the
predictive value of the level of the marker?88
Behavioral studies, including clinical trials, need to estab-
lish the utility of inflammatory markers in increasing pa-
tients’ motivation to adhere to lifestyle modifications or to
comply with pharmacotherapy for the primary or secondary
prevention of CVD. This will be especially important if
additional studies suggest that monitoring hs-CRP or other
markers can be used to gauge disease activity or some other
prognostically meaningful aspect of disease.
Finally, the cost-effectiveness of hs-CRP testing should be
evaluated in clinical studies, preferably as an end point of
clinical trials. Cost-effectiveness studies of diagnostic strate-
gies often are not performed, but important questions need to
be answered to assure wise utilization of resources. Are
additional healthcare costs reduced or increased through the
measurement of hs-CRP? Alternatively, can risk stratification
be improved so low-risk patients can be better identified and
managed less expensively through the addition of hs-CRP to
an initial laboratory-based assessment (eg, lipid profile)?
C. Population Science
Critically needed is a firm understanding of the distribution of
inflammatory markers in the entire population and in impor-
tant population subgroups such as children, the elderly, and
racial/ethnic groups. This might best be accomplished by
pooling existing population study data, or the standardized
analysis of samples from these studies, to describe the factors
affecting hs-CRP levels. A major and urgent need is for
population-based hs-CRP data as CVD risk predictors in
African Americans, Hispanic Americans, Native Americans,
and persons of Asian and South Asian (Indian subcontinent)
heritage. Current “normal” values are derived almost exclu-
sively from European or European-American reference pop-
ulations, leaving open the chance for over- or underclassifi-
cation of risk in these other large population groups.
Similarly, the meaning of elevated hs-CRP levels in
children and young adults needs to be evaluated.89 Given the
models in Figure 2, it is unlikely that these young people have
much atherosclerotic burden. The finding of an elevated
hs-CRP in these individuals nonetheless may provide an early
warning for later risk.
The pooling of data or the standardized assay of blood
samples from large population-based prospective studies
likely is needed to more robustly describe the relationship
between inflammatory markers and CVD end points, includ-
ing the calculation of absolute risk (incidence) for various
strata of hs-CRP, which is not possible from nested case-
control studies. This also would facilitate adjustment for
established cardiovascular risk factors to better define inde-
pendent predictive value and the relative risk for each hs-CRP
stratum. Equally importantly, this pooling will allow the
consistency of the association of elevated hs-CRP to be
described in age, race, and disease subgroups, which would
be important for its clinical utility. Finally, larger sample
sizes will allow the interactions, if any, between hs-CRP
levels and established risk factors to be evaluated and
factored into risk-prediction equations.
VIII. Summary
This working group sought to translate the rapidly growing body
of evidence for inflammation as a key process in atherosclerosis
into clinical and public health practice. Basic science and
epidemiological studies have developed an impressive case that
atherogenesis is essentially an inflammatory response to a
variety of risk factors and the consequences of this response lead
to the development of acute coronary and cerebrovascular
syndromes. Although several cytokines, acute-phase reactants,
and cellular responses to inflammatory stimuli potentially might
be predictive of clinical disease, the laboratory tests to assess
inflammation are limited to those that are employable in clinical
settings, have commercially available assays that can be stan-
dardized, and have adequate precision. On the basis of these
considerations, it is most reasonable to limit current assays of
inflammatory markers to hs-CRP, measured twice, either fasting
or nonfasting, with the average expressed in mg/L, in metabol-
ically stable patients. Relative risk categories (low, average,
high) correspond to approximate tertiles of values (1.0, 1.0 to
3.0, and 3.0 mg/L, respectively), based on an aggregation of
population studies.
hs-CRP has been studied in nested case-control and prospec-
tive studies, which have shown graded, dose-response relation-
ships to clinical CVD that remain after adjustment for other risk
factors, with moderately strong associations between the lower
and upper tertiles (RR 2.0). hs-CRP seems to add predictive
value above that of currently established risk factors. The
evidence, however, is not entirely consistent across published
studies, and in particular, additional prospective studies are
needed to more precisely define risk at various strata and to
assure consistency in other age, sex, and race-ethnicity groups.
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On the basis of the available evidence, the Writing Group
recommends against screening of the entire adult population
for hs-CRP as a public health measure. The Writing Group
does conclude that it is reasonable to measure hs-CRP as an
adjunct to the major risk factors to further assess absolute risk
for coronary disease primary prevention. At the discretion of
the physician, the measurement is considered optional, based
on the moderate level of evidence (Evidence Level C). In this
role, hs-CRP measurement appears to be best employed to
detect enhanced absolute risk in persons in whom multiple
risk factor scoring projects a 10-year CHD risk in the range of
10% to 20% (Evidence Level B). However, the benefits of
this strategy or any treatment based on this strategy remain
uncertain. The finding of a high relative risk level of hs-CRP
(3.0 mg/L) may allow for intensification of medical therapy
to further reduce risk and to motivate some patients to
improve their lifestyle or comply with medications prescribed
to reduce their risk. Individuals at low risk (10% per 10
years) will be unlikely to have a high risk (20%) identified
through hs-CRP testing. Individuals at high risk (20% risk
over 10 years) or with established atherosclerotic disease
generally should be treated intensively regardless of their
hs-CRP levels, so the utility of hs-CRP in secondary preven-
tion appears to be more limited.
In patients with stable coronary disease or acute coronary
syndromes, hs-CRP measurement may be useful as an inde-
pendent marker for assessing likelihood of recurrent events,
including death, myocardial infarction, or restenosis after
percutaneous coronary intervention. However, secondary pre-
ventive interventions with proven efficacy should not be
dependent on hs-CRP levels. Further, serial testing of hs-CRP
should not be used to monitor effects of treatment.
These recommendations should not be interpreted to mean
that the scientific evidence is fully adequate. Randomized trials
in which inflammatory marker testing was the primary interven-
tion have not been performed to provide Level A evidence, nor
have cost-effectiveness analyses been completed to assess addi-
tional costs or cost savings through the use of such tests. The
currently available evidence was assessed in the formulation of
these recommendations. A long list of recommendations for
further research reflects the need to clarify numerous issues.
Nonetheless, basic and epidemiological studies suggest that this
will be a fertile topic for investigations and will help define the
most effective and efficient use of inflammatory markers in the
prediction of CVD.
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